Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
A legfontosabb adatok
- Ki végzi
- Institute of Hematology & Blood Diseases Hospital, China
- Hol
- Tianjin (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 40 fő, tervezett
- Kezdés
- 2026. júl. 10.
- Várható befejezés
- 2027. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Eltrombopag
- A regiszteradat frissítve
- 2026. július 7.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with immune thrombocytopenia (ITP), a disorder with low platelets, where steroid treatment did not work or the disease came back.
- Életkor
- 18 to 80 years
- Nem
- All sexes
- A betegség stádiuma
- ITP diagnosed at least 3 months before joining. Platelet count below 30×10⁹/L within 48 hours before the first dose.
- Korábbi kezelés
- Steroid treatment for ITP must have failed, stopped working, or the disease came back. Emergency ITP treatment must have ended at least 2 weeks before. Steroid maintenance dose must be stable for 2 weeks; immunosuppressants stable for 4 weeks. Anti-CD20 antibody therapy must have ended more than 3 months before.
- Biomarker vagy leletérték
- Platelet count below 30×10⁹/L
A részvétel fő kizáró okai
- Anti-CD20 antibody therapy within 3 months
- HIV, hepatitis B, hepatitis C or other uncontrolled active infection
- Severe bleeding, such as bleeding in the brain or stomach
- Blood clot diseases or heart disease needing treatment
- Pregnant or breastfeeding
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥18 years, regardless of sex
- Clinically diagnosed with immune thrombocytopenia for at least 3 months prior to enrollment. Platelet count <30×10⁹/L within 48 hours before the first dose of study drug
- Previous failure (ineffective, unable to maintain response, or relapse) to first-line standard corticosteroid therapy for ITP as recommended by guidelines
- Any prior emergency treatment for ITP (e.g., corticosteroids, platelet transfusion, intravenous immunoglobulin) must have been completed at least 2 weeks before the first dose
- Patients receiving maintenance corticosteroid therapy must be on a stable dose for at least 2 weeks prior to the first dose; patients receiving immunosuppressants (e.g., azathioprine, danazol, cyclosporine A, tacrolimus, sirolimus, etc.) must be on a stable dose for at least 4 weeks prior to the first dose; anti-CD20 antibody therapy must have been completed >3 months prior; Understand the study procedures and voluntarily provide written informed consent
Ki nem vehet részt
- Received anti-CD20 antibody therapy within 3 months
- Patients whose toxic symptoms from prior treatment before enrollment have not yet resolved
- Uncontrolled primary disease of vital organs, such as malignant tumors, liver failure, heart failure, renal failure, etc
- Positive for HIV
- Uncontrolled active viral or bacterial infections, including positive for hepatitis B, hepatitis C, cytomegalovirus, Epstein-Barr virus, or syphilis
- Extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc
- Currently have cardiac disease requiring treatment, arrhythmia, or hypertension poorly controlled as judged by the investigator
- Patients with thrombotic diseases such as pulmonary embolism, thrombosis, atherosclerosis, etc
- Patients with mental disorders who are unable to give informed consent or undergo study procedures and follow-up normally
- Other serious diseases that may limit the patient's participation in this study (e.g., poorly controlled diabetes; severe cardiac insufficiency; myocardial infarction, unstable arrhythmia, or unstable angina within the past 6 months; gastric ulcer; active autoimmune disease, etc.)
- Pregnant women, suspected pregnancy (positive urinary human chorionic gonadotropin pregnancy test at screening), or lactating patients
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 80 év között vagy?
Helyszínek itt: Kína
- Ethics Committee of Blood disease hospital, Chinese Academy of Medical SciencesTianjin, KínaContact: shuo chen, MasterToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Background: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder. Corticosteroids are first-line therapy, but about one-third of patients relapse or are refractory. Eltrombopag (a TPO-RA) promotes platelet production, yet some patients show no response or relapse upon discontinuation. Telitacicept, a TACI-Fc fusion protein, dual-targets BAFF and APRIL, inhibiting B cell and plasma cell function and reducing autoantibody production, potentially providing synergistic immunomodulatory benefit.
A teljes eredeti leírásKevesebb
Objective: To evaluate the sustained response rate of eltrombopag plus telitacicept vs. eltrombopag alone in patients with steroid-refractory/relapsed ITP.
Design: Randomized, open-label, controlled, exploratory Phase II study. 40 patients planned (20 combination, 20 monotherapy). Combination group: eltrombopag + telitacicept . Monotherapy group: eltrombopag alone for 12 weeks. Monotherapy patients with no response after 4 weeks may cross over to the combination group. After 12 weeks, treatment is stopped and patients are followed until Week 24.
Primary endpoint: Proportion of patients maintaining platelet count ≥30×10⁹/L with no bleeding at 24 weeks post-treatment. Secondary endpoints include platelet response rates during 12 weeks, safety, bleeding events, etc.
Expected results: The combination group is expected to have a significantly higher proportion of patients achieving the primary endpoint without increased adverse events.
Population: Age ≥18, diagnosed ITP ≥3 months, baseline platelets <30×10⁹/L, prior corticosteroid failure.
Safety: Monitoring for bleeding, infection, thrombosis, cytopenia, etc., with dose adjustment/cessation as per protocol.
Conclusion: This study explores whether dual-targeting (platelet production + autoimmune suppression) with eltrombopag and telitacicept can provide more durable remission for steroid-refractory/relapsed ITP patients.
A vizsgálat 2 csoportja
- Monotherapy groupMár használt kezelés, összehasonlításként
Kezelés: Eltrombopag
- Combination groupA vizsgált kezelés
Kezelés: Eltrombopag
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Eltrombopag Combined With Telitacicept Versus Eltrombopag Monotherapy for the Treatment of Immune Thrombocytopenia Refractory or Relapsed to Corticosteroid Therapy: A Randomized Exploratory, Controlled, Open-label, Phase II Clinical Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07687134: ki vehet részt
- A regiszteradat frissítve
- 2026. július 7.